Greenland Mines Ltd
GRML evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Market Cap:
- $13.8M
What it means
What to watch
Prepared research question
What matters most for GRML—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRML
Greenland Mines Ltd (GRML) is a mining company with a biotech division focused on developing a Klotho gene therapy platform for Alzheimer's and aging, having secured patents in Canada and Australia in mid-2026.
Key risk: Limited cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$13.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Greenland Mines Ltd (GRML) is a mining company with a biotech division focused on developing a Klotho gene therapy platform for Alzheimer's and aging, having secured patents in Canada and Australia in mid-2026.
- Cash & equivalents of $9.3M as of 2026-06-30 [sec]
- Net loss of -$3.7M as of 2026-06-30 [sec]
- Shareholders' equity of $57.9M as of 2026-06-30 [sec]
- Secured Canadian Patent No. CA3,005,398 for Klotho gene therapy technology on 2026-07-28 [news]
- Secured Australian Patent No. 2023252508 for Klotho gene therapy platform on 2026-07-10 [news]
What works
- The company has secured patents in Canada and Australia for its Klotho gene therapy platform, indicating progress in intellectual property protection [news].
- The Klotho technology is exclusively licensed from researchers at Universitat Autònoma de Barcelona, suggesting a foundation in academic research [news].
What to weigh
- The company reported a net loss of -$3.7M as of 2026-06-30, indicating ongoing financial losses [sec].
- Cash & equivalents of $9.3M as of 2026-06-30 may limit the company's ability to fund extensive clinical trials without additional capital [sec].
- The company's forward-looking statements are subject to risks including inability to implement business plans and changes in the regulatory environment [news].
From the filings
Quoted directly from source documents.
Canadian patent granted for Klotho gene therapy technology
“Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398, titled "SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND MEMORY””
News · July 28, 2026
Australian patent granted for Klotho gene therapy platform
“IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company's Biotech Division”
News · July 10, 2026
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash & equivalents of $9.3M as of 2026-06-30 may constrain R&D and clinical development [sec].
- Net loss trend — Net loss of -$3.7M as of 2026-06-30 indicates ongoing financial losses [sec].
- Forward-looking statement risks — Company's plans subject to risks including inability to implement business plans and regulatory changes [news].
What to watch
- Progress of Klotho gene therapy platform from patent to clinical trials [news]
- Financial sustainability given cash position and net losses [sec]
- Competitor activity in Alzheimer's gene therapy and related fields [competitor_trial]
Sources: Competitor trials · News · Generated October 7, 2026 · How we verify sources →
Run Greenland Mines Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Greenland Mines Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 1 sell (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
26
Total value held
$3.1M
| Holder | Shares | Value |
|---|---|---|
| meteora capital, llc | 5,373,755 | $1.8M |
| ubs group ag | 1,072,998 | $354K |
| geode capital management, llc | 740,460 | $244K |
| vanguard capital management llc | 577,276 | $191K |
| vanguard fiduciary trust co | 371,703 | $123K |
| brummer multi-strategy ab | 370,049 | $122K |
| two sigma securities, llc | 203,212 | $67K |
| state street corp | 196,400 | $65K |
| blackrock, inc. | 143,459 | $47K |
| xtx topco ltd | 136,771 | $45K |
Showing top 10 of 26 institutional holders of Greenland Mines Ltd. Open the full 13F history after sign-in.
Governance
Frequently asked questions
What is the AI investment thesis for Greenland Mines Ltd?
Greenland Mines Ltd (GRML) is a mining company with a biotech division focused on developing a Klotho gene therapy platform for Alzheimer's and aging, having secured patents in Canada and Australia in mid-2026.
Who is the CEO of Greenland Mines Ltd?
Dr. Joseph A. Sinkule Pharm.D. is the chief executive officer of Greenland Mines Ltd (GRML).
Where is Greenland Mines Ltd headquartered?
Greenland Mines Ltd (GRML) is headquartered in Charlotte, NC, United States.
What therapeutic areas does Greenland Mines Ltd focus on?
Greenland Mines Ltd develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.